AdvaMed

AdvaMed is proud to share the inspiring efforts of our member companies as they launch their powerful diabetes campaigns in honor of #NationalDiabetesMonth. Today, we recognize embecta’s “People First” initiative, which celebrates individuals living with diabetes and works to champion their individuality and well-being as people with unique personalities, passions, and dreams. By recognizing diabetes as just one part of a person’s life, this campaign emphasizes the importance for all of us not to lose sight that people with diabetes are people first. Join us this month in celebrating the resilience and strength of people living with diabetes and learn more about these advocacy efforts!

AdvaMed and our member companies are proud to stand with our partner organizations to promote #WorldDiabetesDay. Organizations like Breakthrough T1D are focused on accelerating the development of life-changing medical technologies and advancing research to improve the lives of those living with Type 1 diabetes. Learn more about their incredible impact on patients’ lives: https://lnkd.in/gfBjJafb

In honor of #NationalDiabetesMonth, we’re featuring as the #DeviceoftheWeek Abbott's world-leading FreeStyle Libre continuous glucose monitoring (CGM) systems, used by more than 6 million people across 60 countries. Libre systems include a sensor, which is applied to the back of the arm for up to 15 days, that sends automatic, minute-by-minute glucose readings to a mobile app or reader. Previously, people with diabetes were required to check their glucose levels several times a day through painful fingersticks. With Libre, checking glucose is as simple as reading a number on a smartphone app, making it much easier for individuals to take action, such as taking insulin or adjusting food and activity, and make progress toward their health goals. Ten years after its initial launch, Libre technology continues to help make #diabetes care easier and more accessible for more people. Learn about how Abbott is a #medtech leader in providing solutions that improve the lives of millions of those living with diabetes. https://bit.ly/3Z0m4iE

On this #VeteransDay, AdvaMed honors all those who have served and sacrificed for our country. Read more about how organizations like MedTechVets is giving back to the veteran community by helping veterans find meaningful employment in the #medtech industry.

Millions of Medicare beneficiaries will have coverage of important diagnostic tools and certain digital therapeutics for mental health treatment, thanks to CMS coverage decisions for 2025. CMS recognized two expandingly popular, valuable imaging technologies: diagnostic radiopharmaceuticals used to diagnose illnesses including Alzheimer’s, Parkinson’s, heart disease, and certain types of cancer; and computed tomography colonography (CTC), also known as a virtual colonoscopy, to provide Medicare beneficiaries access to a minimally invasive colorectal cancer screening tool. With its digital therapeutics decision, CMS opened a conversation on the types of these treatments to cover for Medicare beneficiaries, a critical step as digital treatments arise that could improve mental health conditions in addition to traditional methods. Kudos to CMS for forward-looking action helping Medicare beneficiaries achieve better health. Read more: https://lnkd.in/ettpvcMn

The number-one cancer women in the U.S. are diagnosed with is breast cancer. And at least half of those women have what doctors and scientists call “dense breast tissue,” which often means initial screening options can miss signs of cancer. AdvaMed is calling on Medicare to expand its coverage to include supplemental imaging for women with dense breast tissue, emphasizing its life-saving potential. AdvaMed highlights the critical health equity needs this coverage would address, particularly as many women face barriers such as lack of insurance coverage of or limited access to recommended supplemental screenings. Black women, for example, have higher mortality rates with respect to breast cancer. AdvaMed supports efforts such as the bipartisan Find It Early Act, pending in Congress, and calls on CMS to take the life-saving step of ensuring equitable access to vital imaging technologies for the millions of women in Medicare at risk of breast cancer. https://lnkd.in/eGNwA2Ud

AdvaMed was a proud sponsor of Breakthrough T1D's annual Mid-Atlantic Hope Gala. This event promoted the research necessary to develop the life-saving and life-improving medical technology that allows millions of patients living with Type 1 Diabetes to live healthier lives. #NationalDiabetesMonth

Diabetes management is a daily challenge for millions of patients, but innovation in medical technologies is making life easier. This #NationalDiabetesMonth, we recognize AdvaMed members at the forefront of the diabetes medtech revolution. These companies develop cutting-edge solutions that enhance diabetes care and improve health outcomes. These advancements, like connected continuous glucose monitors and automatic insulin pumps, combined with remote patient monitoring, not only empower individuals to take control of their health but also allow for real-time data sharing with health care providers and for children, their parents. By facilitating connected systems and personalized treatment plans, #medtech is helping patients make informed decisions about their diabetes care. As we continue to witness breakthroughs in diabetes management, AdvaMed remains committed to supporting innovations that enhance patients’ lives. Learn more: https://lnkd.in/eXnGDatt

Today marks one of my favorite events of the year: the AdvaMedDx and Centers for Disease Control and Prevention Industry Day! This event provides a unique platform for our members and CDC leadership to come together and address the pressing health challenges we collectively face. With this year’s focus on emerging and enduring diseases and antimicrobial resistance (AMR), I’m looking forward to insightful discussions and fresh ideas that will drive meaningful collaboration. And a special thanks to Drs. Nirav Shah and Daniel Jernigan, MD MPH for joining the conversation! AdvaMed Abbott BD Beckman Coulter Diagnostics bioMérieux Cepheid Inflammatix, Inc. MeMed Selux Diagnostics, Inc Kristina Shultz

AdvaMed thanks Senators Amy Klobuchar and Dr. Roger Marshall for their continued efforts to expand access to breast cancer screening by introducing the bipartisan Find it Early Act. This important bill would save lives by “guaranteeing that all health insurers cover screening and diagnostic breast imaging at no out-of-pocket costs for women with dense breasts or those at higher risk of breast cancer.”  Women with dense breast tissue are four to six more times likely to develop breast cancer because dense breast tissue can obscure tumors on mammograms. Tragically, many women lack insurance coverage of additional imaging and therefore delay or forgo further testing.  This bill would expand women’s access to receive the scan they need with no cost to the patient. Fittingly, the bill introduction came during Breast Cancer Awareness Month. Read the full AdvaMed thank you letter.